We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Novo Nordisk (NVO) has been experiencing a challenging period, primarily due to regulatory pressures and mixed trial results. Recently, the Centers for Medicare & Medicaid Services (CMS ...
The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.
President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's ...
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
Minnesota Attorney General Keith Ellison says his office has reached a settlement with Novo Nordisk over high insulin ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback